echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes Obes Metab: Diglucagon-like peptide-1/glucagon receptor agonist SAR425899 can significantly improve postprandial glucose metabolism in T2D patients

    Diabetes Obes Metab: Diglucagon-like peptide-1/glucagon receptor agonist SAR425899 can significantly improve postprandial glucose metabolism in T2D patients

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Double glucagon-like peptide-1/glucagon receptor agonist (GLP-1/GCG RA) SAR425899 treatment for 4 weeks has a positive effect on blood sugar control and weight loss in obese type 2 diabetes (T2D) patients.


    Double glucagon-like peptide-1/glucagon receptor agonist (GLP-1/GCG RA) SAR425899 treatment for 4 weeks has a positive effect on blood sugar control and weight loss in obese type 2 diabetes (T2D) patients.


    In this study, researchers randomly divided 70 overweight to obese T2D patients into 3 groups and received SAR425899 (0.


    Blood sugar before and after treatment

    Blood sugar before and after treatment

    Compared with baseline, at the end of treatment, liraglutide significantly improved the basal insulin action (HOMA2 quantitative median: 35%) and insulin secretion (73%), while SAR42899 only significantly increased insulin secretion ( 125%) .


    Liraglutide significantly improved basal insulin action (HOMA2 quantitative median: 35%) and insulin secretion (73%), while SAR42899 only significantly increased insulin secretion (125%)

    Postprandial glucose metabolism before and after treatment

    Postprandial glucose metabolism before and after treatment

    According to the quantitative evaluation of OMM, interventions such as SAR425899 and liraglutide significantly enhanced insulin sensitivity (203% and 36%), basic β cell reactivity (67% and 40%), which was higher than basic β cell reactivity (139 % And 69%) .


    SAR425899 and liraglutide intervention significantly enhanced insulin sensitivity (203% and 36%), basic β cell reactivity (67% and 40%), higher than basic β cell reactivity (139% and 69%)

    In summary, both SAR425899 and liraglutide can improve postprandial blood glucose control in obese type 2 diabetic patients, and moreover.


    Both SAR425899 and liraglutide can improve postprandial blood glucose control in obese type 2 diabetic patients, and moreover.


    Original source:

    Schiavon Michele, Visentin Roberto, Gbel Britta et al.


    org/10.
    1111/dom.
    14394" target="_blank" rel="noopener">Improved Postprandial Glucose Metabolism in Type 2 Diabetes by Dual Glucagon-like Peptide-1 / Glucagon Receptor Agonist SAR425899 in Comparison to Liraglutid

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.